Mar 02, 2023 / 07:00PM GMT
Patrick Bernard Donnelly - Citigroup Inc., Research Division - Senior Analyst
All right. I guess we'll get started. Thanks, everyone, for joining us. I'm Patrick Donnelly, the tools diagnostics CROs analyst here at Citi. Happy to have Brendan Brennan, the CFO of ICON with us here to talk a little CROs. So Brendan, maybe you guys just reported last week, obviously, pretty good quarter, reiterated the guide you had given in January. But you want to maybe just talk through some quick highlights from 4Q into '23 and then we can kind of talk through some things.
Brendan Brennan - ICON Public Limited Company - CFO
Yes, we saw a solid quarter. It was a good end to the year. We were happy with our performance continue to see pretty solid organic growth, particularly on a constant currency basis. So that was continued to be good. But obviously, we were very happy with the margin performance, particularly in 4Q which was very, very solid. And a good jumping off point to think about as we go into '23 now. So we've seen a lot of expansion on EBITDA and we've seen good
ICON PLC at Citi Healthcare & Medtech Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot